Australia’s TPG Telecom Deploys MATRIXX Software to Enable Multiple Brands on a Single, Converged Charging Platform
5.5.2021 03:02:00 EEST | Business Wire | Press release
MATRIXX Software, a global leader in 5G monetization for the communications industry, today announced it has partnered with Australia’s TPG Telecom Limited (ASX: TPG). TPG Telecom operates a number of leading mobile and internet brands including Vodafone, TPG, iiNet, AAPT, Internode and Lebara, providing consumers with a comprehensive portfolio of fixed and mobile products in the Australian telecommunications market.
With their 5G rollout progressing full steam ahead across major Australian cities, TPG Telecom is committed to cementing its place as a strong force for its customers. Looking ahead, as 5G becomes mainstream, TPG Telecom is seeking to unlock new opportunities and offerings resulting from the coming explosion of connected devices. With a goal to improve experience today, while laying the foundation for future innovation, TPG Telecom selected the MATRIXX Digital Commerce Platform to build a flexible, agile service capable of delivering real-time innovation to meet ever-shifting consumer demand.
“At TPG Telecom, the investments we make are designed to provide immediate benefit to our customers today, with an eye towards how we can unlock new opportunities, tomorrow,” said Rob James, Group Chief Digital & Information Officer of TPG Telecom. “Delivering improved value for our shareholders is essential for our success and the MATRIXX platform will enable us with the ability to rapidly innovate and experiment with new monetization models across all of our brands.”
Implemented as part of a full digital transformation program, MATRIXX Digital Commerce Platform enables TPG Telecom to be more commercially competitive, while also reducing costs associated with legacy infrastructure.
“We started with the ambition to consolidate multiple mobile rating platforms whilst still operating as Vodafone Hutchison Australia. Having merged with TPG Corporation to form TPG Telecom, using MATRIXX has further enabled us to ensure all our brands have access to a common rating platform. MATRIXX allows us to consolidate and transform 4G and 5G service monetization by moving to a single real-time platform that’s tightly integrated with our network,” said Easwaren Siva, General Manager Strategy & Architecture of TPG Telecom.
With the first phase completed, MATRIXX is now live for Vodafone branded prepaid services. Later phases of the transformation program will see TPG Telecom migrating mobile postpaid rating across their portfolio of brands, in addition to MVNO, wholesale and enable Standalone 5G charging.
“We are thrilled to be able to help bring TPG Telecom’s vision of improved commercial agility and greater customer experience,” said Glo Gordon, MATRIXX CEO. “Helping to transform how TPG Telecom monetizes today, while giving them a powerful and highly configurable monetization platform for their future innovation, speaks to the core of what we do best — empowering our customers, so that they can empower theirs.”
About TPG Telecom
TPG Telecom Limited was formed by the merger of Vodafone Hutchison Australia Pty Limited and TPG Corporation, formerly named TPG Telecom, on 13 July 2020. The merger brought together two highly complementary businesses, creating the leading challenger full-service telecommunications provider in Australia.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS) enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005060/en/
Contact information
Jennifer Kyriakakis
mediainquiry@matrixx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom